Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19

Mostrar otras versiones (1)

BACKGROUND: Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. It remains to be evaluated for which indications and patient populations the drug is suitable. OBJECTIVES: To assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Reis, Stefanie, Metzendorf, Maria-Inti, Kuehn, Rebecca, Popp, Maria, Gagyor, Ildiko, Kranke, Peter, Meybohm, Patrick, Skoetz, Nicole, Weibel, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688265/
https://www.ncbi.nlm.nih.gov/pubmed/38032024
http://dx.doi.org/10.1002/14651858.CD015395.pub3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688265/
https://www.ncbi.nlm.nih.gov/pubmed/38032024
http://dx.doi.org/10.1002/14651858.CD015395.pub3

Ejemplares similares